Sysmex, bioMérieux Form IVD Joint Venture in Japan | GenomeWeb
NEW YORK (GenomeWeb News) – Japanese diagnostic firm Sysmex will buy a 34 percent equity stake in bioMérieux’s Japanese subsidiary as part of an agreement to form a joint venture that will market bioMérieux’s in vitro diagnostics products in Japan.
 
The joint venture, which will hold the name Sysmex bioMérieux, will market bioMérieux’s entire product line in Japan beginning April 1. Prior to the agreement, bioMérieux’s Japanese operations were managed by its wholly owned subsidiary bioMérieux Japan.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.